Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Short Interest Down 47.8% in October

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) saw a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 73,800 shares, a decrease of 47.8% from the October 15th total of 141,400 shares. Based on an average trading volume of 80,700 shares, the short-interest ratio is presently 0.9 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC increased its position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 596,050 shares of the company’s stock after buying an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 6.42% of the company’s stock.

Ekso Bionics Stock Performance

EKSO traded down $0.01 during trading on Thursday, hitting $0.76. 66,851 shares of the company traded hands, compared to its average volume of 115,384. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. The firm has a market cap of $16.70 million, a P/E ratio of -1.17 and a beta of 1.47. Ekso Bionics has a one year low of $0.72 and a one year high of $3.13. The stock’s fifty day moving average is $1.05 and its 200 day moving average is $1.12.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The firm had revenue of $4.13 million during the quarter, compared to the consensus estimate of $6.00 million. During the same quarter in the previous year, the firm earned ($0.24) earnings per share. As a group, equities analysts predict that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EKSO has been the subject of a number of analyst reports. StockNews.com initiated coverage on Ekso Bionics in a research report on Monday. They issued a “hold” rating for the company. Lake Street Capital dropped their price target on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. Finally, HC Wainwright cut their price target on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.